Bile Duct Cancer

Bile duct cancer is cancer that forms in a bile duct. A bile duct is a tube that carries bile (fluid made by the liver that helps digest fat) between the liver and gallbladder and the intestine.

Test for Bile Duct Cancer

Bile duct cancer is identified, diagnosed, and staged with the help of tests that analyze bile ducts and neighboring organs.

Bile Duct Cancer - Cholangiocarcinoma

Signs and Symptoms of Bile Duct Cancer

What are the Treatment Options for Bile Duct Cancer?

Latest Bile Duct Cancer News and Research

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

Challenges in treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma (CCA).

20 Jun 2024

Study reveals latest cancer trends in Canada

The number of cancer cases and deaths in Canada is expected to increase because of a growing and aging population, but the overall rates of people being diagnosed with and dying from cancer will continue to decline, according to the latest cancer trends research in CMAJ.

13 May 2024

Study sheds light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis

A new study published in the journal Gut has shed light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis, a common condition characterized by the formation of gallstones.

27 Nov 2023

Gene alterations in biliary tract cancer offer potential targets for effective precision therapies

Gene alterations in biliary tract cancer offer potential targets for current or future precision therapies. This is demonstrated by a highly acclaimed study conducted by Karl Landsteiner University of Health Sciences in collaboration with the Medical University of Vienna.

5 Jun 2023

New insights on bile duct and gallbladder cancers

Bile duct and gallbladder cancers are uncommon, with an estimated 12,130 new cases diagnosed this year according to the American Cancer Society.

30 Jan 2023

Primary sclerosing cholangitis: Therapy with synthetic bile acid acts directly on the immune system

Primary Sclerosing Cholangitis (PSC) is a rare, chronic inflammatory disease of the bile ducts and is difficult to treat. Studies conducted by the Division of Gastroenterology and Hepatology at MedUni Wien under the guidance of Michael Trauner (Department of Internal Medicine III) were able to show positive effects from the administration of synthetically produced bile acids and bile acid receptor agonists.

28 Sep 2021

Tissue-specific genetic interactions drive different types of cancer development

Why do alterations of certain genes cause cancer only in specific organs of the human body? Scientists at the German Cancer Consortium, the Technical University of Munich, and the University Medical Center Göttingen have now demonstrated that cells originating from different organs are differentially susceptible to activating mutations in cancer drivers: The same mutation in precursor cells of the pancreas or the bile duct leads to fundamental different outcomes.

19 Jul 2021

Research consortium identifies cell stress mechanisms for chronic inflammatory liver disease

Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat, since its causes have not yet been adequately researched.

30 Mar 2021

Novel targeted therapy blocks metabolic pathways in cancer cells with specific genetic defects

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects.

23 Nov 2020

Persistent-poverty counties face high risk of cancer mortality

Residents of counties that experience persistent poverty face a disproportionately high risk of cancer mortality, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

30 Sep 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.

18 Aug 2020

Scientists find coronavirus' Achilles' heel

A team of scientists at the University of California San Francisco has found out how SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19) invades proteins in the cells that serve as master regulators of key cellular processes.

1 Jul 2020

A promising treatment for chronic inflammatory liver disease

Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat.

14 May 2020

Changes in surface sugarlike molecules help cancer cells to spread

Changes in a specific type of sugarlike molecule, or glycan, on the surface of cancer cells help them to spread into other tissues, according to researchers at the University of California, Davis. Published March 23 in Proceedings of the National Academy of Sciences, the work could lead to diagnostic tests and new therapies to slow or stop the spread of cancers.

25 Mar 2020

Bile duct cancer treatment could be improved by tailored medication

Treatment of patients suffering from bile duct cancer could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research.

16 Feb 2020

Study shows how treatment resistance develops in patients with bile duct cancer

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma.

14 Jan 2020